cerivastatin and Heart-Diseases

After marketing withdrawal of cerivastatin physicians asked several questions regarding the efficacy and safety of statins, the real risk of myopathy, the compared efficacy of all the statins, the reasons why severe adverse events could happen despite several long-term randomized controlled trials, the approval from regulatory agencies. This is the position statement of the Italian Federation of Cardiology. Synthetic answers to previous questions are addressed and few suggestions to avoid that similar conditions should occur again. Finally, the appropriate prescription of statins is recommended.

Topics: Drug and Narcotic Control; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Italy; Practice Guidelines as Topic; Professional Practice; Pyridines; Randomized Controlled Trials as Topic